Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)

项目总结/摘要 这份重新提交的题为"耶鲁大学癌症中心高级培训计划的医生，科学家 （YCC-ATPP）"要求为强化血液学和内科肿瘤学提供五年的支持 (Heme/MedOnc）耶鲁大学医学院（YSM）/耶鲁大学癌症研究培训项目 中心（YCC）。我们培训Heme/MedOnc研究员的记录是强大的。我们的学员已进入专业 在学术和临床血液学和肿瘤学环境中的领导地位和成功。自1987年以来， 151名研究员完成了血红素/MedOnc奖学金计划（最初作为单独的学科;现在作为 自2012年以来的联合计划），以及在过去10年内完成该计划的72名毕业生中的46名 在学术职位上工作，许多人有独立的资金。在最近对癌症的投资支持下 中心由耶鲁大学和耶鲁纽黑文医院，包括增加机构的承诺， 教师招聘近年来（许多同行评审的资金），我们相信结构和支持 T32所提供的技术将使受训者取得更大的成功，并将进一步增加 有成就的独立的医生科学家领导人完成我们的计划。 这T32将建立在卓越的基础上建立在临床培训期间，在我们的 Heme/MedOnc奖学金计划，研究员可以申请该计划。因此， 未来的学员将已经获得医学博士或医学博士/博士学位，完成内科学 住院医师，并在Heme/MedOnc接受2年临床研究员培训。这个T32计划将选择最多的 来自这一群体的高素质和多样化的候选人，他们希望从事癌症研究， 已经制定了许多程序，以确保招聘、高质量的指导和留住 少数族裔研究员人数不足。这种先进的培训计划将提供优秀的指导基本， 翻译，临床和基于结果的癌症研究经验，从高级和专家初级教师在 一个高度合议，协作和一体化的机构环境。该计划旨在提供 必要的财政支持，并确保宝贵的保护时间给我们的研究员进行研究， 他们建立自己的早期作为物理学家，科学家，并铺平道路，走向成功的 学术生涯。沿着这些路线，该计划包括职业发展规划和指导 委员会，包括在受训者研究领域具有知识和经验的科学家和医生， 在整个项目期间提供指导。在训练结束后，我们的目标是， 由该T32支持的个人将发展独立工作所需的技能，包括 设计，启动和完成研究项目的能力，并有效地撰写赠款和手稿。 T32将坚定地将Heme/MedOnc研究员定位为独立的临床，转化或基础癌症 未来的研究领导者

PROJECT SUMMARY/ABSTRACT This resubmission titled “Yale Cancer Center Advanced Training Program for Physician-scientists (YCC-ATPP)” requests five years of support for an intensive hematology and medical oncology (Heme/MedOnc) fellowship research training program at the Yale School of Medicine (YSM)/Yale Cancer Center (YCC). Our record of training Heme/MedOnc fellows is strong. Our trainees have gone on to major positions of leadership and success in academic and clinical hematology and oncology settings. Since 1987, 151 fellows have completed the Heme/MedOnc Fellowship Program (originally as separate disciplines; now as a joint program since 2012), and 46 of the 72 graduates who completed the program within the last 10 years work in academic positions, many with independent funding. Bolstered by the recent investment in our cancer center by Yale University and Yale-New Haven Hospital, including increased institutional commitment and faculty recruitment in recent years (many with peer-reviewed funding), we believe the structure and support provided by this T32 will allow trainees to achieve even greater success and will further increase the numbers of accomplished independent physician-scientist leaders completing our program. This T32 will build on a foundation of excellence established during clinical training in our Heme/MedOnc Fellowship Program, from which fellows will be able to apply to this program. As such, the prospective trainees will have already received an MD or MD/PhD degree, completed internal medicine residency, and 2 years of clinical fellowship training in Heme/MedOnc. This T32 program will select the most highly qualified and diverse candidates from this group who wish to pursue a career in cancer research and numerous procedures have been put in place to ensure the recruitment, quality mentorship, and retention of under-represented minority fellows. This advanced training program will provide outstanding mentored basic, translational, clinical, and outcome-based cancer research experiences from senior and expert junior faculty in a highly collegial, collaborative, and integrative institutional environment. This program is designed to provide essential financial support and ensure precious protected time is given to our fellows for research, allowing them to establish themselves early on as physician-scientists, and paving the way towards a successful academic career. Along these lines, the program includes career development planning and mentorship committees including scientists and physicians with knowledge and experience in the trainee’s research field to provide guidance throughout the length of the program. At the conclusion of their training, it is our goal that individuals supported by this T32 will have developed the skills necessary to function independently, including the ability to design, initiate, and complete research projects, and to effectively write grants and manuscripts. The T32 will firmly position Heme/MedOnc fellows as independent clinical, translational, or basic cancer researcher leaders of tomorrow.